巴楚医学

目的：探讨不同方式注射硝普钠对急诊经皮冠状动脉介入(PCI)术中无复流的治疗效果。方法：选取2019年1月～2021年1月我院收治的STEMI急诊PCI术中发生无复流现象的患者104例，以掷硬币法分为研究组与对照组，每组各52例。对照组为微导管注射硝普钠，研究组为球囊扩张导管注射硝普钠，观察两组患者的术后疗效。结果：术后研究组的靶血管校正TIMI帧数低于对照组，冠脉血流分级优于对照组，左心室舒张末期内径低于对照组，左心室射血分数、ST段完全恢复率均高于对照组，无复流的再发率低于对照组，差异均具有统计学意义(P<0.05)。两组患者术后主要不良心血管事件发生率无明显差异(P>0.05)。结论：STEMI患者急诊PCI术中发生无复流时以球囊扩张导管方式注射硝普钠可有效促进冠脉血流恢复，且不会增加主要不良心血管事件的发生率。

Objective: To investigate the effect of sodium nitroprusside injection in different ways on no-reflow during primary percutaneous coronary intervention(PCI) process. Methods: A total of 104 patients with ST-segment elevation myocardial infarction(STEMI) undergoing primary PCI complicated with no-reflow from January 2019 to January 2021 were selected and divided into the study group and the control group using coin tossing method, with 52 cases in each group. Patients in the control group and the study group were injected with sodium nitroprusside through microcatheter and balloon dilated catheter, respectively. Then, the postoperative efficacy of the two groups was compared. Results: Compared to the control group, the target vessel corrected TIMI frame count was lower, the coronary flow classification was better, the left ventricular end diastolic diameter was lower, the left ventricular ejection fraction and ST segment complete recovery rate were higher, the incidence of recurrent no-reflow were lower in the study group(all P<0.05). There was no significant difference in the incidence of major adverse cardiovascular events between these two groups(P>0.05). Conclusion: In STEMI patients undergoing primary PCI complicated with no-reflow, injection of sodium nitroprusside by balloon dilation catheter can effectively promote coronary blood flow recovery without increasing the incidence of major adverse cardiovascular events.